8-K: Salarius Pharmaceuticals Secures Nasdaq Extension Amidst Strategic Merger with Decoy Therapeutics

Salarius Pharmaceuticals has received an additional extension from Nasdaq to regain compliance with listing standards, while progressing its definitive merger with preclinical biopharmaceutical company Decoy Therapeutics.

Summary

• Salarius Pharmaceuticals received an additional extension from Nasdaq until late July 2025 to regain compliance with the $2.5 million Stockholders' Equity Standard (Nasdaq Listing Rule 5550(b)(1)).
• The company must also regain compliance with the $1.00 Minimum Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)) by early August 2025.
• This follows previous non-compliance notices from Nasdaq on March 26, 2025 (Equity Standard) and April 23, 2025 (Minimum Bid Price Requirement).
• A definitive merger agreement with Decoy Therapeutics, Inc., a privately held preclinical biopharmaceutical company, was announced on January 13, 2025.
• Post-merger, Decoy investors are expected to own approximately 92.4% of the outstanding shares of the combined company, and Salarius stockholders are expected to own approximately 7.6%, exclusive of any shares issued in future financing.
• The combined company will be named Decoy Therapeutics and will be led primarily by Decoy's co-founders and executives, along with Salarius's Chief Financial Officer.
• Decoy's pipeline includes peptide conjugate therapeutics engineered by its IMP3ACT platform, targeting unmet needs in respiratory infectious diseases and gastroenterology (GI) oncology indications.
• The combined company intends to incorporate Salarius's oral small molecule protein degrader SP-3164 into a highly targeted peptide-based proteolysis targeting chimeras (PROTACs) drug candidate.
• Within the next 12 months, Decoy expects to advance its lead asset, a pan-coronavirus antiviral, to the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).
• Progress is also expected on Decoy's other programs, including a broad-acting antiviral against flu, COVID-19, and RSV, and a peptide drug conjugate targeting GI cancers.
• Data may be reported within the next 12 months from an investigator-initiated Phase 1/2 clinical study at MD Anderson Cancer Center evaluating Salarius's seclidemstat for myelodysplastic syndrome and chronic myelomonocytic leukemia.

Sentiment

Score: 3

Explanation: While the company secured an extension from Nasdaq and is pursuing a merger that brings a new pipeline, the underlying issues of non-compliance with Nasdaq listing rules persist and required an extension. The significant dilution for existing shareholders in the merger and the ongoing financial challenges indicate a precarious position, despite the potential future value of Decoy's pipeline.

Positives

• Granted an additional extension by Nasdaq to regain compliance with listing standards, avoiding immediate delisting.
• Progressing with a definitive merger agreement with Decoy Therapeutics, which brings a new, innovative pipeline and platform (IMP3ACT) focused on peptide conjugate therapeutics.
• Decoy Therapeutics has attracted financing from institutional investors and significant non-dilutive capital from sources such as the Massachusetts Life Sciences Seed Fund, Google AI startup program, NVIDIA Inception program, and BARDA through BLUE KNIGHT.
• The combined company plans to advance a pan-coronavirus antiviral to IND filing within 12 months and progress other promising programs.
• Salarius's SP-3164 will be incorporated into a new peptide-based PROTAC drug candidate, potentially enhancing its therapeutic application.

Negatives

• Salarius remains non-compliant with Nasdaq's $2.5 million Stockholders' Equity Standard and $1.00 Minimum Bid Price Requirement.
• The company failed to meet the initial early July 2025 deadline for regaining compliance with the Equity Standard, necessitating a further extension.
• A reverse stock split during the prior one-year period made Salarius ineligible for the standard 180-calendar day compliance period for the Minimum Bid Price Requirement.
• Salarius's failure to comply with the Minimum Bid Price Requirement prevented Nasdaq from entertaining a Compliance Plan for the Equity Standard.
• Existing Salarius stockholders are expected to own only approximately 7.6% of the combined company post-merger, indicating substantial dilution.

Risks

• The conditions to the closing of the proposed merger may not be satisfied, including uncertainties as to the timing of the consummation.
• Salarius and Decoy may not be able to consummate the merger.
• Salarius may not regain compliance with Nasdaq continued listing standards within the required timeframe.
• The combined company may not satisfy the initial Nasdaq listing standards within the required timeframe.
• Salarius may not receive any additional extensions from Nasdaq if compliance is not regained within the required timeframe.
• Risks related to Salarius's ability to estimate and manage its operating expenses and its expenses associated with the proposed merger pending the closing.
• The combined company may not achieve the synergies expected from the proposed merger.
• Salarius and the combined company may not obtain sufficient financing to execute on their business plans.
• Risks related to Decoy's products and development plans, including unanticipated issues with any IND application process.
• The potential of the IMP3ACT platform may not be fully realized.

Future Outlook

The combined company, to be named Decoy Therapeutics, plans to advance Decoy's lead pan-coronavirus antiviral asset to an Investigational New Drug (IND) application filing with the FDA within the next 12 months. Progress is also expected on other programs, including a broad-acting antiviral and a peptide drug conjugate targeting GI cancers. Additionally, data from an investigator-initiated Phase 1/2 clinical study of Salarius's seclidemstat for hematologic cancers may be reported within the next 12 months. The merger is expected to facilitate multiple value-creating inflection points with Decoy's pipeline and IMP3ACT platform.

Management Comments

• "The proposed transaction, if consummated, is expected to facilitate multiple value-creating inflection points with Decoy’s pipeline of peptide conjugate therapeutics engineered by its IMP3ACT platform."
• "During the next 12 months, Decoy expects to advance its lead asset, a pan-coronavirus antiviral, to the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA), and to make progress with its other programs including a broad-acting antiviral against flu, COVID-19 and respiratory syncytial virus (RSV), and a peptide drug conjugate targeting GI cancers."

Industry Context

The merger represents a strategic pivot for Salarius, a clinical-stage oncology company, into the preclinical-stage infectious disease and gastroenterology oncology space via Decoy Therapeutics' peptide conjugate platform. This aligns with a broader industry trend of biopharmaceutical companies seeking innovative platforms (like AI/machine learning-driven drug design) and diversifying pipelines, especially into areas with unmet needs like novel antivirals and targeted cancer therapies. The focus on peptide conjugates and PROTACs reflects current trends in drug discovery for improved specificity and efficacy.

Comparison to Industry Standards

• The document does not provide specific financial or clinical trial comparisons to other companies or projects.
• The Nasdaq listing compliance issues (below $1.00 bid price and below $2.5 million equity) indicate that Salarius is significantly underperforming compared to the minimum financial health standards required for major exchange listing, which is a common challenge for smaller, clinical-stage biotechs.
• Decoy's non-dilutive funding from sources like Google AI startup program, NVIDIA Inception, and BARDA suggests a level of external validation for its technology platform (IMP3ACT) and pipeline, which is a positive indicator for a preclinical company in the competitive biotech landscape.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders (Salarius): Face significant dilution, with expected ownership of only 7.6% of the combined company. Their investment is contingent on the successful merger and the new company's pipeline success, as well as the company regaining Nasdaq compliance.
• Shareholders (Decoy): Expected to own approximately 92.4% of the combined company, indicating a highly favorable outcome for them, contingent on merger closing and future performance.
• Employees: The combined company will be led primarily by Decoy's management, with Salarius's CFO retaining a role. This suggests potential changes or integration challenges for other Salarius employees.
• Customers/Patients: Potential for new therapeutic options in respiratory infectious diseases and GI oncology if Decoy's pipeline advances successfully.
• Creditors: The company's financial health and Nasdaq compliance issues could impact creditworthiness, though the merger aims to improve the overall financial and strategic position.

Next Steps

• Regain compliance with Nasdaq's Stockholders' Equity Standard by late July 2025.
• Regain compliance with Nasdaq's Minimum Bid Price Requirement by early August 2025.
• Consummate the merger transaction with Decoy Therapeutics, subject to closing conditions.
• Advance Decoy's lead pan-coronavirus antiviral asset to an IND application filing with the FDA within the next 12 months.
• Make progress with other Decoy programs, including a broad-acting antiviral and a peptide drug conjugate targeting GI cancers.
• Potentially report data from the investigator-initiated Phase 1/2 clinical study of Salarius's seclidemstat within the next 12 months.
• Incorporate Salarius's SP-3164 into a highly targeted peptide-based PROTACs drug candidate.

Key Dates

Recommendation

Keywords

Salarius Pharmaceuticals, Decoy Therapeutics, Nasdaq compliance, merger agreement, biopharmaceutical, IMP3ACT platform, peptide conjugate therapeutics, antiviral, oncology, IND application, FDA, SP-3164, seclidemstat, stockholders equity, minimum bid price, delisting risk, biotechnology, preclinical, clinical-stage